A PHASE I/II, OPEN-LABEL, MULTI-COHORT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CEVOSTAMAB IN PRIOR B CELL MATURATION ANTIGEN-EXPOSED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Primary Objective

This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in participants with R/R MM. Sections 3.1 and 3.2 present the primary and secondary efficacy objectives for the study expressed using the estimand framework in accordance with the ICH E9(R1) statistical principles for clinical trials (FDA 2021b).

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Locations

CTRC Inpatient
University of Colorado Hospital

Principal Investigator
Photograph of Daniel Sherbenou

Daniel Sherbenou

Study ID

Protocol Number: 22-0931

More information available at ClinicalTrials.gov: NCT05535244

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers